Amneal Pharmaceuticals, Inc. AMRX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $181.32M+41.7% | $127.93M+122% | $57.62M+12.4% | $51.24M+58.1% | $32.42M+144% | ||
| $33.51M+4.9% | $31.95M+3.2% | $30.96M+3.7% | $29.85M+5.5% | $28.3M+1.9% | ||
| $19.51M-13.0% | $22.43M-12.1% | $25.53M-10.5% | $28.53M-2.0% | $29.11M0.0% | ||
| $97.7M-19.0% | $120.57M-13.2% | $138.83M— | —— | —— | ||
| $128.72M+47.9% | $87.03M-26.8% | $118.83M-9.4% | $131.12M-0.4% | $131.59M+0.8% | ||
| $9.37M-56.1% | $21.32M-69.1% | $69M+49.7% | $46.11M-23.6% | $60.34M-74.3% | ||
| $33.06M+63.9% | $20.17M— | —— | —— | —— | ||
| -$4.91M-3.7% | -$4.73M+22.1% | -$6.08M-16.7% | -$5.21M-250% | -$1.49M+2.4% | ||
| —— | —— | —— | —— | —— | ||
| $305.84M-10.0% | $339.99M+3.7% | $327.76M-6.6% | $351.08M+14.4% | $306.92M+4.0% | ||
| $65.08M-7.1% | $70.06M+10.4% | $63.45M-6.8% | $68.09M+21.8% | $55.89M+7.6% | ||
| $19.16M+23.5% | $15.51M+18.3% | $13.11M+41.0% | $9.3M+1.6% | $9.15M-37.5% | ||
| —— | —— | —— | —— | —— | ||
| -$116.18M-3.5% | -$112.26M-35.5% | -$82.87M-2.2% | -$81.12M-32.9% | -$61.03M+3.1% | ||
| $2.83B+5.0% | $2.69B+1,485% | $170M— | —— | —— | ||
| $1.93M-1.6% | $1.96M+25.8% | $1.56M+2.4% | $1.52M+27.4% | $1.2M+3.6% | ||
| $44.94M+102% | $22.28M-0.3% | $22.34M-0.3% | $22.41M+0.1% | $22.38M+181% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | -$234.4M-2.9% | -$227.8M-7.6% | ||
| -$2.23M-32.9% | -$1.68M+24.0% | -$2.21M-45.7% | -$1.52M-15.7% | -$1.31M-30.3% | ||
| $136.01M-30.1% | $194.52M+21.5% | $160.06M+370% | $34.05M+103% | $16.78M-13.1% | ||
| $197.98M+0.1% | $197.85M-8.8% | $217.05M-9.4% | $239.62M-6.2% | $255.33M-3.1% | ||
| $27.39M+28.4% | $21.33M-10.2% | $23.74M+26.8% | $18.73M+129% | $8.19M-50.0% | ||
| $19.51M-13.0% | $22.43M-12.1% | $25.53M-10.5% | $28.53M-2.0% | $29.11M0.0% | ||
| $206.6M-7.6% | $223.57M-7.0% | $240.48M-2.0% | $245.36M+1.9% | $240.82M+2.0% | ||
| —— | —— | —— | $6.7M+422% | -$2.08M+71.0% | ||
| —— | —— | —— | -$2K+99.8% | -$1.04M-116% | ||
| —— | —— | —— | $50.12M+4.8% | $47.82M-12.2% | ||
| $33.06M+63.9% | $20.17M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $75.65M-12.0% | $85.96M-6.8% | $92.27M-1.3% | $93.5M-3.9% | $97.3M+0.8% | ||
| -$4.91M-3.7% | -$4.73M+22.1% | -$6.08M-16.7% | -$5.21M-250% | -$1.49M+2.4% | ||
| $19.16M+23.5% | $15.51M+18.3% | $13.11M+41.0% | $9.3M+1.6% | $9.15M-37.5% | ||
| $33.51M+16.4% | $28.78M+95.9% | $14.69M+21.3% | $12.11M+42.2% | $8.51M+1.2% | ||
| —— | —— | —— | —— | —— | ||
| —— | $2.09M+33.3% | $1.57M+50.0% | $1.05M+100% | $523.5K— | ||
| —— | $74.97M+33.3% | $56.25M+49.9% | $37.52M+99.6% | $18.8M+26,374% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $0— | ||
| -$2.91B-3.4% | -$2.81B-213% | $2.48B+14,952% | -$16.72M+0.3% | -$16.77M+91.1% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $27.39M+28.4% | $21.33M-10.2% | $23.74M+26.8% | $18.73M+129% | $8.19M-50.0% | ||
| —— | —— | —— | —— | —— | ||
| $240.77M-10.8% | $269.93M+2.1% | $264.31M-6.6% | $282.99M+12.7% | $251.03M+3.2% | ||
| $240.77M-10.8% | $269.93M+2.1% | $264.31M-6.6% | $282.99M+12.7% | $251.03M+3.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Amneal Pharmaceuticals, Inc. generate?
- Amneal Pharmaceuticals, Inc. (AMRX) generated $305.8M in operating cash flow over the trailing twelve months.
- What is Amneal Pharmaceuticals, Inc.'s free cash flow?
- After $65.1M of capital expenditures, Amneal Pharmaceuticals, Inc.'s free cash flow was $240.8M over the trailing twelve months, down 4.1% year over year.
- Where does Amneal Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Amneal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
